Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L. «Prevalence and Type Distribution of High-Risk Human Papillomavirus Infection in Women Undergoing Voluntary Cervical Cancer Screening in Italy». J Med Virol. 2009 Mar;81(3):529-35. doi:10.1002/jmv.21347.

Australian Institute of Health and Welfare. 2013. «Cervical screening in Australia 2010-2011. National Cervical Screening Program». AIHW Cancer series no. 76. http://www.aihw.gov.au/WorkArea/ DownloadAsset.aspx?id=60129543399.

Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. «Incidence of Cervical Lesions in Danish Women before and after Implementation of a National HPV Vaccination Program». Cancer Causes Control. 2014 Jul;25(7):915-22. doi:10.1007/s10552-014-0392-4.

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. «A review of human carcinogens – Part B: biological agents». Lancet Oncol. 2009 Apr;10(4):321-2.

Brotherton JM1, Saville AM, May CL, Chappell G, Gertig DM. «Human Papillomavirus Vaccination Is Changing the Epidemiology of High-Grade Cervical Lesions in Australia». Cancer Causes Control. 2015 Jun;26(6):953-4. doi:10.1007/s10552-015-0568-6.

Brown P1, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. «How to Formulate Research Recommendations». BMJ. 2006 Oct 14;333(7572):804-6. doi:10.1136/bmj.38987.492014.94.

Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. «Human Papillomavirus and Related Diseases in Europe. Summary Report 2015-04-08». ICO Information Centre on HPV and Cancer (HPV Information Centre). http://www.hpvcentre.net/statistics/reports/XEX.pdf.

Capra G, Giovannelli L, Bellavia C, Migliore MC, Caleca MP, Perino A, et al. «HPV Genotype Prevalence in Cytologically Abnormal Cervical Samples from Women Living in South Italy». Virus Res. 2008 May;133(2):195-200. doi:10.1016/j.virusres.2007.12.020.

Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, et al. «Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy». Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2389-400. doi:10.1158/1055-9965.EPI-10-0131.

Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. «Short Term Persistence of Human Papillomavirus and Risk of Cervical Precancer and Cancer: Population Based Cohort Study». BMJ. 2009 Jul 28;339:b2569. doi:10.1136/bmj.b2569.

Castle PE1, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. «Performance of Carcinogenic Human Papillomavirus (HPV) Testing and HPV16 or HPV18 Genotyping for Cervical Cancer Screening of Women Aged 25 Years and Older: A Subanalysis of the ATHENA Study». Lancet Oncol. 2011 Sep;12(9):880-90. doi:10.1016/S1470-2045(11)70188-7.

Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. «Ongoing Decline in Genital Warts among Young Heterosexuals 7 Years after the Australian Human Papillomavirus (HPV) Vaccination Programme». Sex Transm Infect. 2015 May;91(3):214-9. doi:10.1136/sextrans-2014-051813.

Ciotti M, Paba P, Bonifacio D, Di Bonito L, Benedetto A, Favalli C. «Single or Multiple HPV Types in Cervical Cancer and Associated Metastases». Oncol Rep. 2006 Jan;15(1):143-8.

Clifford GM, Smith JS, Aguado T, Franceschi S. «Comparison of HPV Type Distribution in High-Grade Cervical Lesions and Cervical Cancer: A Meta-Analysis». Br J Cancer. 2003 Jul 7;89(1):101-5. doi:10.1038/sj.bjc.6601024.

Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. «Human Papillomavirus Types in Invasive Cervical Cancer Worldwide: A Meta-Analysis». Br J Cancer. 2003 Jan 13;88(1):63-73. doi:10.1038/sj.bjc.6600688.

Commissione Oncologica Nazionale. 1996. «Proposte operative in tema di prevenzione secondaria del cervico-carcinoma uterino. In: Linee guida elaborate dalla Commissione Oncologica Nazionale, in applicazione di quanto previsto dal Piano Sanitario Nazionale per il triennio 1994-96, relativo all’azione programmata “Prevenzione e cura delle malattie oncologiche, concernenti l’organizzazione della prevenzione e dell’assistenza in oncologia”». Supplemento Ordinario. n. 127. Gazzetta Ufficiale.

De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. «Sustained Efficacy and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine up to 7.3 Years in Young Adult Women». Vaccine. 2010 Aug 31;28(38):6247-55. doi:10.1016/j.vaccine.2010.07.007.

Deleré Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T. «The Efficacy and Duration of Vaccine Protection against Human Papillomavirus: A Systematic Review and Meta-Analysis». Dtsch Arztebl Int. 2014 Sep 1;111(35-36):584-91. doi:10.3238/arztebl.2014.0584.

Del Mistro A, Salamanca HF, Trevisan R, Bertorelle R, Parenti A, Bonoldi E, et al. «Human Papillomavirus Typing of Invasive Cervical Cancers in Italy». Infect Agent Cancer. 2006 Dec 27;1:9. doi:10.1186/1750-9378-1-9.

de Sanjose S, Alemany L, Tous S, Bosch FX; HPV RIS TT Study Group. «HPV types in early-onset cervical cancer – Authors’ reply». Lancet Oncol. 2011 Feb; 12(2):117-18.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. «Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: A Retrospective Cross-Sectional Worldwide Study». Lancet Oncol. 2010 Nov;11(11):1048-56. doi:10.1016/S1470-2045(10)70230-8.

Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. «Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial». JAMA. 2013 May 1;309(17):1793-802. doi:10.1001/jama.2013.1625.

Donati S, Giambi C, Declich S, Salmaso S, Filia A, Ciofi degli Atti ML. «Knowledge, Attitude and Practice in Primary and Secondary Cervical Cancer Prevention among Young Adult Italian Women». Vaccine. 2012 Mar 9;30(12):2075-82. doi:10.1016/j.vaccine.2012.01.057.

Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. «Population-Level Impact and Herd Effects Following Human Papillomavirus Vaccination Programmes: A Systematic Review and Meta-Analysis». Lancet Infect Dis. 2015 May;15(5):565-80. doi:10.1016/S1473-3099(14)71073-4.

Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, et al. «Comparison of Long-Term Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine and HPV-6/11/16/18 Vaccine in Healthy Women Aged 18-45 Years: End-of-Study Analysis of a Phase III Randomized Trial». Hum Vaccin Immunother. 2014;10(12):3435-45. doi:10.4161/hv.36121.

European Commission. 2015a. «Commission implementing decision amending the marketing authorisation granted by Decision C(2006)4281 for “Gardasil – Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)”, a medicinal product for human use. – Annex 1». http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_Product_Information/human/000703/WC500021142.pdf.

European Commission. 2015b. «Commission implementing decision amending the marketing authorisation granted by Decision C(2007)4440 for “Cervarix – Human PapillomaVirus-16 and Human Papilloma Virus 18 L1 proteins”, a medicinal product for human use – Annex I». http://ec.europa.eu/health/documents/community-register/2015/20151210133701/anx_133701_en.pdf.

Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. 2014. «Long-term Study of a Quadrivalent Human Papillomavirus Vaccine». Pediatrics. 2014 Sep;134(3):e657-65. doi:10.1542/peds.2013-4144.

Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlée F. «The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change». Arch Med Res. 2009 Aug;40(6):478-85. doi:10.1016/j.arcmed.2009.06.003.

Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, et al. «Prevalence and Distribution of Single and Multiple HPV Infections in Cytologically Abnormal Cervical Samples from Italian Women». Virus Res. 2007 May;125(2):176-82. doi:10.1016/j.virusres.2006.12.017.

Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Menso S, De Nictolis M, et al. «The Role of Human Papillomavirus DNAs in Cervical Carcinoma and Risk of Lymph Node Metastasis: Association with 72-Kilodalton Metalloproteinase Immunostaining». Cancer. 1998 Mar 1;82(5):886-92.

Giambi C. 2014. «Stato di avanzamento della campagna vaccinale per l’HPV: dati di copertura vaccinale al 31/12/2014 – Rapporto semestrale (dati aggiornati di tutte le Regioni)». Reparto di Epidemiologia di Malattie Infettive, Istituto Superiore di Sanità. http://www.epicentro.iss.it/problemi/hpv/pdf/Aggiornamento_HPV_31122014Completo.pdf.

Giambi C, Del Manso M, De Mei B, D’Ancona F, Giovanelli I, Cattaneo C; Gruppo di lavoro VALORE. 2013. «Progetto VALORE (VAlutazione LOcale e REgionale delle campagne di vaccinazione contro l’HPV): favorire l’adesione consapevole alla vaccinazione.». Istituto Superiore di Sanità. Rapporti ISTISAN 13/47. http://www.iss.it/binary/publ/cont/13_47_web.pdf.

Giorgi Rossi P, Bisanzi S, Paganini I, Di Iasi A, Angeloni C, Scalisi A, et al. «Prevalence of HPV High and Low Risk Types in Cervical Samples from the Italian General Population: A Population Based Study». BMC Infect Dis. 2010 Jul 20;10:214. doi:10.1186/1471-2334-10-214.

Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, et al; Gruppo di lavoro HPV Prevalenza. «[Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy]». Epidemiol Prev. 2012 Mar-Apr;36(2):108-19.

Giorgi Rossi P, Ronco G. «HPV Types in Early-Onset Cervical Cancer». Lancet Oncol. 2011 Feb;12(2):117; author reply 117-8. doi:10.1016/S1470-2045(11)70015-8.

Giorgi Rossi P, Sideri M, Carozzi FM, Vocaturo A, Buonaguro FM, Tornesello ML, et al. «HPV Type Distribution in Invasive Cervical Cancers in Italy: Pooled Analysis of Three Large Studies». Infect Agent Cancer. 2012 Oct 12;7(1):26. doi:10.1186/1750-9378-7-26.

GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. «Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years». Lancet. 2009 Dec 12;374(9706):1975-85. doi:10.1016/S0140-6736(09)61567-1.

Guan P, Clifford GM, Franceschi S. «Human Papillomavirus Types in Glandular Lesions of the Cervix: A Meta-Analysis of Published Studies». Int J Cancer. 2013 Jan 1;132(1):248-50. doi:10.1002/ijc.27663.

Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. «Human Papillomavirus Types in 115,789 HPV-Positive Women: A Meta-Analysis from Cervical Infection to Cancer». Int J Cancer. 2012 Nov 15;131(10):2349-59. doi:10.1002/ijc.27485.

Harper DM. «Impact of Vaccination with Cervarix (trade Mark) on Subsequent HPV-16/18 Infection and Cervical Disease in Women 15-25 Years of Age». Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi:10.1016/j.ygyno.2008.06.029.

Intesa tra il Governo, le Regioni e le Province autonome di Trento e Bolzano. 2015. «Piano Nazionale Prevenzione Vaccinale (PNPV) 2012-2014. Intesa ai sensi dell’articolo 8, comma 6, della legge 5 giugno 2003, n°131». http://www.statoregioni.it/Documenti/DOC_035260_54%20csr%20punto%204.pdf.

Intesa tra il Governo, le Regioni e le Provincie autonome. 2007. «Strategie per l’offerta attiva del vaccino contro l’infezione da HPV in Italia». http://www.statoregioni.it/Documenti/DOC_016696_264%20csr.pdf.

Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. «A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women». N Engl J Med. 2015 Feb 19;372(8):711-23. doi:10.1056/NEJMoa1405044.

Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. «Introduction and Sustained High Coverage of the HPV Bivalent Vaccine Leads to a Reduction in Prevalence of HPV 16/18 and Closely Related HPV Types». Br J Cancer. 2014 May 27;110(11):2804-11. doi:10.1038/bjc.2014.198.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. «The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women with Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice». J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9. doi:10.1093/jnci/dji187.

Kjær SK, Frederiksen K, Munk C, Iftner T. «Long-Term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence». J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88. doi:10.1093/jnci/djq356.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al; Costa Rica Vaccine Trial and PATRICIA study groups. «Efficacy of Fewer than Three Doses of an HPV-16/18 AS04-Adjuvanted Vaccine: Combined Analysis of Data from the Costa Rica Vaccine and PATRICIA Trials». Lancet Oncol. 2015 Jul;16(7):775-86. doi:10.1016/S1470-2045(15)00047-9.

Laconi S, Greco M, Milia G, Pellegrini-Bettoli P, Pani P, Laconi E, et al. «[Simultaneous detection and typing of human papillomavirus in cervical biopsies using PCR-reverse hybridization]». Pathologica. 2000 Dec;92(6):524-9.

Lehtinen M, Dillner J. «Clinical Trials of Human Papillomavirus Vaccines and beyond». Nat Rev Clin Oncol. 2013 Jul;10(7):400-10. doi:10.1038/nrclinonc.2013.84.

Lillo F, Galli L, Lodini S, Taccagni G, Ferrari A, Origoni M. «Extralesional Detection and Load of Human Papillomavirus DNA: A Possible Marker of Preclinical Tumor Spread in Cervical Cancer». J Low Genit Tract Dis. 2008 Jul;12(3):204-9. doi:10.1097/LGT.0b013e318161429e.

Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. «Human Papillomavirus Type Distribution in 30,848 Invasive Cervical Cancers Worldwide: Variation by Geographical Region, Histological Type and Year of Publication». Int J Cancer. 2011 Feb 15;128(4):927-35. doi:10.1002/ijc.25396.

Lipsitch M. «Bacterial Vaccines and Serotype Replacement: Lessons from Haemophilus Influenzae and Prospects for Streptococcus Pneumoniae». Emerg Infect Dis. 1999 May-Jun;5(3):336-45. doi:10.3201/eid0503.990304.

Lu B, Kumar A, Castellsagué X, Giuliano AR. «Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis». BMC Infect Dis. 2011 Jan 12;11:13. doi:10.1186/1471-2334-11-13.

Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, et al. «Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of GardasilTM in Adult Women». PLoS One. 2013 Dec 31;8(12):e83431. doi:10.1371/journal.pone.0083431.

Mariani L, Monfulleda N, Alemany L, Vizza E, Marandino F, Vocaturo A, et al. «Human Papillomavirus Prevalence and Type-Specific Relative Contribution in Invasive Cervical Cancer Specimens from Italy». BMC Cancer. 2010 Jun 4;10:259. doi:10.1186/1471-2407-10-259.

Ministero della Salute. Direzione Generale della prevenzione. Screening Oncologici. 2006. «Raccomandazioni per la pianificazione e l’esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro, della cervice uterina e del cancro del colon retto.» Roma.

Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. «Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine». Hum Vaccin Immunother. 2014;10(8):2147-62. doi:10.4161/hv.29532.

Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. «Induction of Immune Memory Following Administration of a Prophylactic Quadrivalent Human Papillomavirus (HPV) Types 6/11/16/18 L1 Virus-like Particle (VLP) Vaccine». Vaccine. 2007 Jun 21;25(26):4931-9. doi:10.1016/j.vaccine.2007.03.049.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. «Efficacy of a Prophylactic Adjuvanted Bivalent L1 Virus-like-Particle Vaccine against Infection with Human Papillomavirus Types 16 and 18 in Young Women: An Interim Analysis of a Phase III Double-Blind, Randomised Controlled Trial». Lancet. 2007 Jun 30;369(9580):2161-70. doi:10.1016/S0140-6736(07)60946-5.

Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, et al. «Occurrence of Vaccine and Non-Vaccine Human Papillomavirus Types in Adolescent Finnish Females 4 Years Post-Vaccination». Int J Cancer. 2012 Dec 15;131(12):2832-8. doi:10.1002/ijc.27586.

Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. «Reduction of Low- and High-Grade Cervical Abnormalities Associated with High Uptake of the HPV Bivalent Vaccine in Scotland». Br J Cancer. 2014 Oct 28;111(9):1824-30. doi:10.1038/bjc.2014.479.

Rolla M, Berretta R, Patrelli TS, Merisio C, Gramellini D, Fadda GM, et al. «A Perspective Study on Correlation between HPV DNA and Lymph Nodes in Surgically Treated Cervical Carcinoma Patients. Preliminary Data». Eur J Gynaecol Oncol. 2009;30(5):557-61.

Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. «Sustained immunogenicity of the HPV-16/28 AS04-adjuvanted vaccine administered as a 2-dose schedule in adolescent girls: 5-year clinical data and modelling predictions». In Abstract 177, OS11. Dublin. http://cmoffice.kenes.com/cddemo/data/HtmlApp/main.html

Romanowski B. «Long Term Protection against Cervical Infection with the Human Papillomavirus: Review of Currently Available Vaccines». Hum Vaccin. 2011 Feb;7(2):161-9.

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, et al. «[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]». Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72.

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. «Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer: Follow-up of Four European Randomised Controlled Trials». Lancet. 2014 Feb 8;383(9916):524-32. doi:10.1016/S0140-6736(13)62218-7.

Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. «Sustained Immunogenicity and Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine: Up to 8.4 Years of Follow-Up». Hum Vaccin Immunother. 2012 Mar;8(3):390-7. doi:10.4161/hv.18865.

Sandø N, Kofoed K, Zachariae C, Fouchard J. «A Reduced National Incidence of Anogenital Warts in Young Danish Men and Women after Introduction of a National Quadrivalent Human Papillomavirus Vaccination Programme for Young Women–an Ecological Study». Acta Derm Venereol. 2014 May;94(3):288-92. doi:10.2340/00015555-1721.

Sandri MT, Riggio D, Salvatici M, Passerini R, Zorzino L, Boveri S, et al. «Typing of Human Papillomavirus in Women with Cervical Lesions: Prevalence and Distribution of Different Genotypes». J Med Virol. 2009 Feb;81(2):271-7. doi:10.1002/jmv.21382.

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, et al. «A Long-Term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia among 20,000 Women in the Portland Kaiser Cohort Study». Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409. doi:10.1158/1055-9965.EPI-11-0206.

Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Gałaj A, Schulze K, et al. «Persistence of Immune Responses to the HPV-16/18 AS04-Adjuvanted Vaccine in Women Aged 15-55 Years and First-Time Modelling of Antibody Responses in Mature Women: Results from an Open-Label 6-Year Follow-up Study». BJOG. 2015 Jan;122(1):107-18. doi:10.1111/1471-0528.13070.

Serraino D, Gini A, Taborelli M, Ronco G, Giorgi-Rossi P, Zappa M, et al. «Changes in Cervical Cancer Incidence Following the Introduction of Organized Screening in Italy». Prev Med. 2015 Jun;75:56-63. doi:10.1016/j.ypmed.2015.01.034.

Sideri M, Cristoforoni P, Casadio C, Boveri S, Igidbashian S, Schmitt M, et al. «Distribution of Human Papillomavirus Genotypes in Invasive Cervical Cancer in Italy: A Representative, Single Institution Case Series». Vaccine. 2009 May 29;27 Suppl 1:A30-3. doi:10.1016/j.vaccine.2008.12.028.

Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. «Efficacy, Safety, and Immunogenicity of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Women Older than 25 Years: 4-Year Interim Follow-up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study». Lancet. 2014 Dec 20;384(9961):2213-27. doi:10.1016/S0140-6736(14)60920-X.

Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. «Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Lesions: A Meta-Analysis Update». International Journal of Cancer 121 (3): 621-32. doi:10.1002/ijc.22527.

Spinillo Arsenio, Barbara Gardella, Marianna Roccio, Paola Alberizzi, Enrico Maria Silini, e Barbara Dal Bello. 2014. «Untypable Human Papillomavirus Infection and Risk of Cervical Intraepithelial Neoplasia among Women with Abnormal Cervical Cytology». Int J Cancer. 2007 Aug 1;121(3):621-32. doi:10.1002/jmv.23938.

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. «Fall in Human Papillomavirus Prevalence Following a National Vaccination Program». J Infect Dis. 2012 Dec 1;206(11):1645-51. doi:10.1093/infdis/jis590.

Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. «Assessment of Herd Immunity and Cross-Protection after a Human Papillomavirus Vaccination Programme in Australia: A Repeat Cross-Sectional Study». Lancet Infect Dis. 2014 Oct;14(10):958-66. doi:10.1016/S1473-3099(14)70841-2.

The FUTURE II Study Group. «Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions». N Engl J Med. 2007 May 10;356(19):1915-27.doi:10.1056/NEJMoa061741.

Thomsen LT, Frederiksen K, Munk C, Junge J, Iftner T, Kjaer SK, et al. «Long-Term Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse according to High-Risk Human Papillomavirus Genotype and Semi-Quantitative Viral Load among 33,288 Women with Normal Cervical Cytology». Int J Cancer. 2015 Jul 1;137(1):193-203. doi:10.1002/ijc.29374.

Tornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G; Italian HPV Working Group. «Prevalence of Alpha-Papillomavirus Genotypes in Cervical Squamous Intraepithelial Lesions and Invasive Cervical Carcinoma in the Italian Population». J Med Virol. 2006 Dec;78(12):1663-72. doi:10.1002/jmv.20752.

Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, et al. «Human Papillomavirus (HPV) Genotypes and HPV16 Variants and Risk of Adenocarcinoma and Squamous Cell Carcinoma of the Cervix». Gynecol Oncol. 2011 Apr;121(1):32-42. doi:10.1016/j.ygyno.2010.12.005.

Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL. «Promising Strategies for Cervical Cancer Screening in the Post-Human Papillomavirus Vaccination Era». Sex Health. 2010 Sep;7(3):376-82 doi:10.1071/SH10022.

Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, et al. «Correlation of High-Risk Human Papillomavirus Genotypes Persistence and Risk of Residual or Recurrent Cervical Disease after Surgical Treatment». J Med Virol. 2008 Aug;80(8):1434-40. doi:10.1002/jmv.21198.

Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. «High Sustained Efficacy of a Prophylactic Quadrivalent Human Papillomavirus Types 6/11/16/18 L1 Virus-like Particle Vaccine through 5 Years of Follow-Up.» Br J Cancer. 2006 Dec 4;95(11):1459-66.doi:10.1038/sj.bjc.6603469.

Voglino G, Poso F, Privitera S, Parisio F, Ghiringhello B, Gordini G, et al. «[The role of human papillomavirus in cyto-histological practice: distribution and prevalenceof hig-risk strains (16, 18, 31, 33, and 35) in intraepithelial lesions and neoplasia of the uterine cervix]». Pathologica. 2000 Dec;92(6):516-23.

von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. «European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination». Papillomavirus Research 2015 Dec;1:22-31. doi:10.1016/j.pvr.2015.06.006.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. «Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide». J Pathol. 1999 Sep;189(1):12-9. doi:10.1002/(SICI)1096-9896(199909)189:1<12:AID-PATH431>3.0.CO;2-F.

WHO/RHR. 2006. «Preparing for the introduction of HPV vaccines: policy and programme guidance for countries» http://www.who.int/reproductivehealth/publications/cancers/RHR_06.11/en/.

Zerbini M, Venturoli S, Cricca M, Gallinella G, De Simone P, Costa S, et al. «Distribution and Viral Load of Type Specific HPVs in Different Cervical Lesions as Detected by PCR-ELISA». J Clin Pathol. 2001 May;54(5):377-80.